glp-1 latest use tripled among non-diabetics, reaching $5.8B in 2022 Poll: 1 in 8 Adults

JAMA Dermatol 155(10):11981200

It helps maintain muscle mass, keeps hunger in check, and even enhances the release of hormones that promote a feeling of fullness

Additionally, the exenatide treated group exhibited lower dopamine transporter availability relative to placebo, and exploratory analyses indicated that exenatide significantly reduced both heavy drinking days and total alcohol intake among obese patients (Klausen et al., 2022)

Contact us if youd like to request reuse of a visual asset

Metabolism (1995) 44:4751

If these drugs do receive an addiction indication, ensuring equitable access will be a critical challenge